← Back to Home

Helping Cancer-Fighting T Cells Go Further: MEK Inhibition Reveals the Energy Cost of Exhaustion

Continuously producing cancer-killing proteins may impose an unsustainable metabolic cost on T cells. A preclinical study found that inhibiting MEK can prolong cell survival while weakening immediate attack capacity, revealing a balance that immunotherapy must strike.

By SURL BioNews

One challenge in cancer immunotherapy is how to keep attacking T cells going until the end. When tumors persist, these cells may gradually become “exhausted,” struggling to sustain an effective response. A study focuses on the energy cost of the attack itself: reducing the burden of producing cancer-killing proteins might preserve longer-lasting fighting capacity, but at the cost of reduced immediate firepower.

Led by Santosha Vardhana’s team at Memorial Sloan Kettering Cancer Center (MSK), with Tanmana Mitra as first author, the study was published online in *Immunity* on July 13, 2026. Through cell and animal experiments, the team identified the signaling kinase MEK as an important link between persistent antigen stimulation, energy demands, and terminal exhaustion in CD8-positive T cells. ScienceDaily covered the findings in October; the evidence remains preclinical.

The study showed that prolonged stimulation of T-cell receptors increases cellular demand for the energy molecule ATP, followed by NADH accumulation within mitochondria, increased reactive oxygen species, and impaired mitochondrial function. This gives “exhaustion” a more concrete metabolic picture: even as their function declines, cells may remain highly active internally, continuing to bear substantial energy costs.

MEK signaling is one factor driving these costs. The team found that sustained MEK activation increases the overall rate of protein synthesis. After MEK inhibition, nutrient uptake and mitochondrial NADH accumulation decreased, while proliferative capacity recovered. Gene expression analysis also showed reduced transcription of genes associated with effector function and terminal exhaustion, while transcription of genes associated with T-cell memory was preserved.

Conserving energy, however, comes at a cost. MSK’s account of the research noted that blocking MEK allowed T cells to survive longer in models of harsh tumor environments, while also reducing production of the proteins used to kill cancer cells. Longer cell survival therefore cannot be directly equated with better tumor control. How to balance persistence and attack strength is the central question in translating this strategy into treatment.

Vardhana suggested that prolonging cell survival might be more meaningful when tumors are larger and fewer T cells are available to attack. If the immune response already has a chance to clear a tumor quickly, reducing firepower may not be beneficial. This remains a therapeutic concept requiring validation and cannot yet serve as a basis for patient selection. The team also proposed possible combinations with immune checkpoint inhibitors, CAR T cells, tumor-infiltrating lymphocytes, and bispecific antibodies.

MEK inhibitors have already been approved for cancer treatment, providing tools to explore in further research, but those existing approvals do not establish that this anti-exhaustion strategy can improve patient outcomes. When to intervene, how extensively to inhibit MEK, and whether sufficient cancer-killing capacity can be maintained while preserving T cells all require further study. The value of this work lies in identifying a biological mechanism that can be investigated to understand the strength and duration of immune responses.

References

  1. ScienceDaily Top Health
  2. Memorial Sloan Kettering Cancer Center
  3. Immunity via PubMed